SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI

Core Insights - SeaStar Medical Holding Corporation has completed enrollment in the SAVE Registry, a Post-Approval Study required by the FDA to confirm the safety of QUELIMMUNE therapy for children with acute kidney injury (AKI) due to sepsis [1][5] - The SAVE Registry has enrolled 50 patients, and the company plans to report 28-day safety results to the FDA after data analysis [1][2] - Early results from the SAVE Registry indicate valuable clinical outcomes data on the safety and probable benefit of QUELIMMUNE therapy [2][6] Company Overview - SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure [10] - The QUELIMMUNE therapy is the only FDA-approved product for life-threatening AKI due to sepsis in critically ill pediatric patients [10] - The Selective Cytopheretic Device (SCD) therapy has received Breakthrough Device Designation for six therapeutic indications by the FDA, facilitating a faster approval process [10] Product and Technology - QUELIMMUNE therapy is designed for children aged 22 years or younger with AKI due to sepsis, requiring renal replacement therapy [5] - The SCD therapy aims to neutralize over-active immune cells and stop cytokine storms, which can lead to destructive hyperinflammation [9] - Clinical studies have shown a 77% survival rate with QUELIMMUNE therapy, representing a 50% reduction in loss of life compared to historical data [6][7] Clinical Studies and Trials - The NEUTRALIZE-AKI pivotal trial is evaluating the safety and efficacy of SCD therapy in 339 adults with AKI in the ICU [8] - The primary endpoint of the NEUTRALIZE-AKI trial is a composite of 90-day mortality or dialysis dependency [8] - Recent data from the SAVE Registry aligns with previous clinical trial results, reinforcing the therapy's effectiveness [7] Market and Adoption - QUELIMMUNE therapy has been adopted by several nationally recognized children's medical centers in the U.S., indicating strong interest and potential for market expansion [2] - The complexities of setting up and running patient registries have previously hindered faster adoption, but the company is optimistic about future growth [2]